NO994485L - Styrt frigivelse av farmasöytiske midler i det fremre kammer i öyet - Google Patents

Styrt frigivelse av farmasöytiske midler i det fremre kammer i öyet

Info

Publication number
NO994485L
NO994485L NO994485A NO994485A NO994485L NO 994485 L NO994485 L NO 994485L NO 994485 A NO994485 A NO 994485A NO 994485 A NO994485 A NO 994485A NO 994485 L NO994485 L NO 994485L
Authority
NO
Norway
Prior art keywords
anterior chamber
eye
controlled release
pharmaceutical agents
agents
Prior art date
Application number
NO994485A
Other languages
English (en)
Norwegian (no)
Other versions
NO994485D0 (no
Inventor
Miles A Galin
Joseph C Salamone
Stanley C Israel
Original Assignee
Miles A Galin
Joseph C Salamone
Stanley C Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles A Galin, Joseph C Salamone, Stanley C Israel filed Critical Miles A Galin
Publication of NO994485D0 publication Critical patent/NO994485D0/no
Publication of NO994485L publication Critical patent/NO994485L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
NO994485A 1997-03-18 1999-09-16 Styrt frigivelse av farmasöytiske midler i det fremre kammer i öyet NO994485L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/819,255 US5972326A (en) 1995-04-18 1997-03-18 Controlled release of pharmaceuticals in the anterior chamber of the eye
PCT/US1998/005320 WO1998041171A1 (en) 1997-03-18 1998-03-18 Controlled release of pharmaceuticals in the anterior chamber of the eye

Publications (2)

Publication Number Publication Date
NO994485D0 NO994485D0 (no) 1999-09-16
NO994485L true NO994485L (no) 1999-11-16

Family

ID=25227627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994485A NO994485L (no) 1997-03-18 1999-09-16 Styrt frigivelse av farmasöytiske midler i det fremre kammer i öyet

Country Status (29)

Country Link
US (1) US5972326A (sh)
EP (1) EP1027015B1 (sh)
JP (2) JP2001516258A (sh)
KR (1) KR20000076347A (sh)
CN (1) CN1251979A (sh)
AP (1) AP9901655A0 (sh)
AT (1) ATE288719T1 (sh)
AU (1) AU6471698A (sh)
BG (1) BG103806A (sh)
BR (1) BR9808282A (sh)
CA (1) CA2282427C (sh)
DE (1) DE69828993T2 (sh)
DK (1) DK1027015T3 (sh)
EA (1) EA002004B1 (sh)
EE (1) EE9900413A (sh)
ES (1) ES2237836T3 (sh)
HU (1) HUP0001818A3 (sh)
ID (1) ID23917A (sh)
IL (1) IL131955A0 (sh)
IS (1) IS5172A (sh)
NO (1) NO994485L (sh)
NZ (1) NZ337654A (sh)
OA (1) OA11158A (sh)
PL (1) PL335801A1 (sh)
PT (1) PT1027015E (sh)
SK (1) SK127099A3 (sh)
TR (1) TR199902253T2 (sh)
WO (1) WO1998041171A1 (sh)
YU (1) YU46899A (sh)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
ES2302881T3 (es) * 1997-07-29 2008-08-01 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
DK172900B1 (da) * 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
CA2386822A1 (en) 1999-11-01 2001-05-10 Alcon, Inc. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
ES2168190B1 (es) * 1999-11-23 2003-11-01 Iglesias Javier Lopez Uso intraocular de una combinacion de viscoelastico y anestesico (material viscoanestesico).
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
AU2001247410B2 (en) 2000-03-14 2005-05-12 Alcon, Inc. Viscoelastics for use in middle ear surgery
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
ES2225573T3 (es) 2000-07-28 2005-03-16 Alcon, Inc Composiciones farmaceuticas que contienen tobramicina y goma xantana.
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2002040056A2 (en) * 2000-11-06 2002-05-23 Alcon, Inc Carrageenan viscoelastics for ocular surgery
US20020176841A1 (en) * 2001-03-19 2002-11-28 Praecis Pharmaceuticals Inc. Pharmaceutical formulations for sustained release
PT1385452E (pt) * 2001-07-23 2006-12-29 Alcon Inc Dispositivo de administração de fármacos oftálmicos
JP2005519873A (ja) 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
US20040101561A1 (en) * 2002-11-13 2004-05-27 Jafari Masoud R. Combinations of viscoelastics for use during surgery
US7820194B2 (en) * 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
CN1658894A (zh) * 2002-02-14 2005-08-24 默克专利股份有限公司 用于治疗眼病的方法和组合物
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1534313B1 (en) 2002-07-30 2012-10-17 Omeros Corporation Ophthalmologic irrigation solutions and method
ES2319400T3 (es) 2002-07-31 2009-05-07 Durect Corporation Composiciones deposito inyectables y empleo de las mismas.
DK1539101T3 (da) 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
CA2554489A1 (en) * 2004-01-28 2005-08-11 The Regents Of The University Of California Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
CN1921833A (zh) * 2004-02-26 2007-02-28 博士伦公司 藻酸盐粘弹性组合物、使用方法及包装
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US20060251551A1 (en) * 2005-05-09 2006-11-09 Brian Johnson Apparatus and method for ozone gas distribution
WO2007124397A2 (en) * 2006-04-21 2007-11-01 Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
ITPD20060202A1 (it) * 2006-05-22 2007-11-23 Univ Degli Studi Trieste Miscele polimeriche di polisaccaridi anionici e cationici e loro impiego
US20080021068A1 (en) * 2006-07-24 2008-01-24 Akorn, Inc. Aqueous gel formulation and method for inducing topical anesthesia
US20090123527A1 (en) * 2006-07-24 2009-05-14 Akorn, Inc. Method of inducing topical anesthesia and transdermal patch
PL2818184T3 (pl) 2007-11-16 2019-06-28 Aclaris Therapeutics, Inc. Kompozycje i sposoby do leczenia plamicy
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
JP5722217B2 (ja) 2008-09-02 2015-05-20 アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用
FR2938187B1 (fr) 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
ES2621380T3 (es) * 2009-04-02 2017-07-03 Allergan, Inc. Hidrogeles con forma de cabello para aumento de tejidos blandos
CN102038953B (zh) * 2009-10-14 2012-07-18 上海昊海生物科技股份有限公司 一种眼科手术前局部麻醉用组合物及其制备方法和用途
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
KR20180117211A (ko) * 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
EP2544652A2 (en) 2010-03-12 2013-01-16 Allergan Industrie SAS A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition.
EP3520827B1 (en) 2010-03-22 2022-05-25 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
FR2968996B1 (fr) * 2010-12-17 2013-04-12 Anteis Sa Formulation aqueuse injectable sterile utilisee en ophtalmologie
EP2675455A4 (en) * 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
KR102015676B1 (ko) 2011-06-03 2019-10-21 알러간, 인코포레이티드 항산화제를 포함하는 피부 충전제 조성물
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
CN102949755B (zh) * 2011-08-16 2015-04-08 上海建华精细生物制品有限公司 一种含有局麻药物的医用腔道窥镜润滑胶制备方法及其用途
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
EP2581079B1 (en) 2011-10-11 2016-12-07 BioPolymer GmbH & Co. KG Combination of hyaluronic acid and prilocaine
GB2501943B (en) * 2012-05-10 2020-09-23 Zeiss Carl Meditec Ag Ophthalmic viscoelastic device
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
RU2563232C1 (ru) * 2014-04-01 2015-09-20 Общество с ограниченной ответственностью "КОЛЕТЕКС" Способ получения лечебного гидрогеля
EP3620184A1 (en) 2014-09-30 2020-03-11 Allergan Industrie, SAS Stable hydrogel compositions including additives
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
FR3036035B1 (fr) * 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
BR112019002967A2 (pt) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
DE202021003113U1 (de) 2021-10-04 2021-10-21 Qais Aburok Wirkstoffkombination aus Lidocain und Allcin gegen Irritationen der Haut und Schleimhäute

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1113760A (en) * 1966-12-16 1968-05-15 Barnes Hind Lab Inc Ophthalmic composition
IL50250A (en) * 1975-08-27 1980-01-31 Hydrophilics Int Inc Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4303637A (en) * 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5093126A (en) * 1987-09-26 1992-03-03 Alcon Laboratories, Inc. Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
US4902692A (en) * 1988-03-18 1990-02-20 Iolab Corporation Method and composition for ophthalmic anesthesia using rodocaine
JPH0236128A (ja) * 1988-07-25 1990-02-06 Kiyoshi Kita 眼内注射剤
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5007913A (en) * 1989-09-19 1991-04-16 Alcon Surgical, Inc. Apparatus and method for implantation of intraocular lenses
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber

Also Published As

Publication number Publication date
NO994485D0 (no) 1999-09-16
TR199902253T2 (xx) 1999-12-21
BG103806A (en) 2000-04-28
SK127099A3 (en) 2000-07-11
IS5172A (is) 1999-09-07
CA2282427A1 (en) 1998-09-24
HUP0001818A2 (hu) 2000-10-28
PT1027015E (pt) 2005-06-30
US5972326A (en) 1999-10-26
DE69828993D1 (de) 2005-03-17
NZ337654A (en) 2001-04-27
AP9901655A0 (en) 1999-09-30
CN1251979A (zh) 2000-05-03
PL335801A1 (en) 2000-05-22
OA11158A (en) 2003-04-18
DE69828993T2 (de) 2006-03-30
WO1998041171A1 (en) 1998-09-24
ID23917A (id) 2000-05-25
EA199900811A1 (ru) 2000-02-28
EE9900413A (et) 2000-04-17
BR9808282A (pt) 2000-05-16
EA002004B1 (ru) 2001-10-22
KR20000076347A (ko) 2000-12-26
JP2010269155A (ja) 2010-12-02
ATE288719T1 (de) 2005-02-15
DK1027015T3 (da) 2005-06-13
EP1027015A1 (en) 2000-08-16
EP1027015B1 (en) 2005-02-09
JP2001516258A (ja) 2001-09-25
HUP0001818A3 (en) 2001-11-28
AU6471698A (en) 1998-10-12
YU46899A (sh) 2000-10-30
EP1027015A4 (en) 2001-06-27
ES2237836T3 (es) 2005-08-01
IL131955A0 (en) 2001-03-19
CA2282427C (en) 2004-05-18

Similar Documents

Publication Publication Date Title
NO994485L (no) Styrt frigivelse av farmasöytiske midler i det fremre kammer i öyet
MX9708043A (es) Liberacion controlada de farmacos mioticos y midriaticos en la camara anterior.
BR9106330A (pt) Tiofeno sulfonamidas uteis como inibidores da anidrase carbonica
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
WO2001010907A3 (en) Therapeutic polypeptides and methods for using same
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20060155L (no) Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
HUP0401605A2 (hu) Szembetegségek kezelésére szolgáló integrin gátlók
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
ATE319458T1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
ES2147616T3 (es) Derivados de piperidina con actividad antagonista del paf.
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
TW200503689A (en) Pharmaceutical compositions of atorvastatin
SE8304616L (sv) Retinaskyddsmedel for behandling av intraokulera blodningar, myopiska korioretinala dystrofier, medfodda retinadystrofier och retinabrennsar samt for forebyggande av skador vid laserkoagulering
BR9706891A (pt) Composto, medicamento, composição farmacêutica e composição cosmética.
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
SE9201425D0 (sv) Method and means for preventing constriction of the pupil in the eye
SE8901149D0 (sv) Medel foer inducering respektive foerhindrande av pupillkonstriktion i oegat
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
ES2138668T3 (es) Nuevos derivados de peptidos terapeuticamente activos en la cadena de coagulacion sanguinea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application